Targeting the oncogenic Met receptor by antibodies and gene therapy

E. Vigna, P. M. Comoglio

Research output: Contribution to journalArticlepeer-review


The receptor for hepatocyte growth factor (HGF), a tyrosine kinase encoded by the Met oncogene, has a crucial role in cancer growth, invasion and metastasis. It is a validated therapeutic target for 'personalized' treatment of a number of malignancies. Therapeutic tools prompting selective, robust and highly effective Met inhibition potentially represent a major step in the battle against cancer. Antibodies targeting either Met or its ligand HGF, although challenging, demonstrate to be endowed with promising features. Here we briefly review and discuss the state of the art in the field.

Original languageEnglish
Pages (from-to)1883-1889
Number of pages7
Issue number15
Publication statusPublished - May 26 2014

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics
  • Medicine(all)


Dive into the research topics of 'Targeting the oncogenic Met receptor by antibodies and gene therapy'. Together they form a unique fingerprint.

Cite this